Leqembi, Formerly Lecanemab, Gets FDA Approval to Treat Alzheimer's | Alzheimer's News Today
Leqembi, Eisai and Biogen’s amyloid-targeted antibody therapy, has earned FDA approval for the treatment of Alzheimer’s disease.| Alzheimer's News Today
Leqembi, Eisai and Biogen’s amyloid-targeted antibody therapy, has earned FDA approval for the treatment of Alzheimer’s disease.| Alzheimer's News Today
Eisai is seeking FDA approval of a monthly maintenance IV regimen of Leqembi for people with early Alzheimer’s disease.| Alzheimer's News Today
